Home
overview

The success of a new pharmaceutical product and its delivery relies heavily on its active response to the human system. Essentially what is covered in this multi-disciplinary field, is the interaction between a delivery system and the biological barriers it must overcome. Several research methods are utilised in an effort to improve the efficacy of drug delivery with a continuing trend towards the utilisation of nanotechnologies.

SMi’s 5th Annual Conference on Controlled Release promises to showcase the latest technologies relating to oral, pulmonary, transdermal and injectable drug delivery. Our world class panel will cover a range of topics including particle engineering for enhanced solubility, characterising drugs and excipients, and sustained release preparations with proteins and polypeptides. Significant industry perspectives will be addressed through selective innovative case studies with explicit emphasis given to developments in drug delivery and controlled release using nanotechnology. Part of our focus will also include a look at Cancer-related drug delivery/controlled release.

Speakers from Controlled Release - Recent trends and future technologies include:

Professor Randall Mrsny, President-elect, Controlled Release Society & Founder & Chief Scientific Officer, Trinity Biosystems
Dr Joel Richard, Director, Pharmaceutical Development, Serono
Dr Steve Dinh, Vice President, Research & Technology Development, Emisphere Technologies
Dr Gurvinder Singh Rekhi, Director, Research & Development, Elan Drug Technologies
Dr Tomas Landh, Research Scientist, Novo Nordisk
Dr Paul Gellert, Senior Scientist, AstraZeneca
Dr Tom Tice, Executive Vice President & Chief Scientific Officer, Brookwood Pharmaceuticals

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Paul Gellert

Paul Gellert, Senior Principal Scientist, AstraZeneca

9:10 AN OVERVIEW OF CONTROLLED RELEASE

Randall Mrsny

Randall Mrsny, President Elect Controlled Research Society, Cardiff University

  • Status and applications of emerging technologies
  • Development of these dosage forms
  • Evaluating and selecting a delivery system
  • Implication of delivery technologies on future products
  • The status of companion and complimentary devices
  • 9:50 DEVELOPING NEW CONTROLLED RELEASE TECHNOLOGIES

    Marshall Whiteman

    Marshall Whiteman, Vice President, Technology Development, Phoqus Pharmaceuticals

  • Defining the delivery need
  • Choosing the right delivery technology
  • Evaluating costs and IP environment
  • Defining feasibility
  • Integration in product development
  • 10:30 Morning Coffee

    11:00 DEVELOPING NEW TECHNOLOGIES FOR PEPTIDES AND PROTEINS

    Pierandrea Esposito

    Pierandrea Esposito, Senior Consultant, Drug Delivery & Development , SiTec Consulting

  • Development of biopharmaceuticals products: new challenges and needs
  • Selecting the right delivery strategies
  • Controlled release systems: new materials, micro and nanosystems
  • New molecular designs and engineering
  • 11:40 BIOSILICON

    Mark Parry-Billings

    Mark Parry-Billings, Director, Research and Development, pSiMedica

  • Manufacture, IP and toxicology for the novel biomaterial
  • Pharmaceutical, preclinical and clinical experience
  • Working examples of broad product utility
  • 12:20 Networking Lunch

    13:50 ORAL CONTROLLED RELEASE PRODUCTS

    Gurvinder Rekhi

    Gurvinder Rekhi, Director, Research & Development, Elan Pharmaceutical Research Corp

  • Fundamentals of oral controlled release
  • Pitfalls of scaling-up to manufacturing level
  • Multi-particulate, multi-layer bead systems
  • Site-specific delivery systems
  • Compression coating for CR
  • 14:30 EMERGING TECHNOLOGIES IN ORAL DELIVERY

    Steven Dinh

    Steven Dinh, Vice President, Research & Technology Development, Emisphere Technologies

  • Overview of protein and peptide based delivery
  • Mechanism of oral delivery technology
  • Challenges and opportunities in product development
  • Case study: from research to clinical development
  • 15:10 Afternoon Tea

    15:40 NEW GROUNDS FOR LIPOSOME-BASED DELIVERY SYSTEMS

    Steffen Panzner

    Steffen Panzner, Chief Executive Officer, Novosom AG

  • Unmet needs in protein delivery
  • Open pore vs liposome systems
  • Sustained and burst free release from liposomes
  • Oligo delivery - the big gap to therapeutics?
  • Amphotric liposomes as a novel class of liposomes
  • Efficient delivery of oligos in therapeutic settings – exploring current strategies
  • 16:20 CLINICAL INVESTIGATIONS FOR ASSESSING CR FEASIBILITY

    Alyson Connor

    Alyson Connor, Senior Scientist, Pharmaceutical Profiles Group

  • Mapping out regiospecific absorption to make an early decision on oral CR options
  • Using engineering-based drug delivery capsules to deliver prototype formulations to enhance drug permeability and/or solubility
  • Pharmacoscintigraphy studies (gamma scintigraphy & pharmacokinetic data) to demonstrate if the formulation is delivering the right dose at the right time in the right place
  • Understanding the impact of GI physiology on oral CR performance using pharmacoscintigraphy
  • 17:40 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Steve Ellul

    Steve Ellul, Director, Business Development, Eurand

    9:10 SUSTAINED DRUG DELIVERY VIA THE LUNGS

    Stephen Farr

    Stephen Farr, Vice President, Research & Development, Aradigm Corporation

  • Review of existing trends
  • Identifying unmet needs in pulmonary drug delivery
  • Comparing and contrasting systemic and pulmonary routes
  • Evaluating various pulmonary delivery strategies
  • Controlled release of drugs via pulmonary delivery
  • Barriers to effective sustained release
  • 9:50 DRUG DELIVERY WITH LONG-ACTING PARENTERALS

    Tom Tice

    Tom Tice, Executive Vice President, Chief Scientific Officer, Brookwood Pharmaceuticals

  • Microparticles
    - Injectable solid implants
    - Hydrophobic drug microparticles
  • Development of long-acting parenterals - Materials - Manufacturing
  • Long-acting parenterals - On the market - In the clinic
  • The future of long-acting parenterals
  • 10:30 Morning Coffee

    11:00 PHYSIOLOGICAL BARRIERS TO ORAL DRUG ABSORPTION

    Henry Flanner

    Henry Flanner, Director Pharmaceutical Research, Advancis Pharmaceuticals

  • The transport of drugs
  • Mass transport and drug absorption limitations
  • Properties of common physiological barriers
  • Assessing physiological barriers
  • The effects of excipients on physiological barriers
  • Modelling techniques in controlled release of absorption limited drugs
  • 11:40 POORLY WATER SOLUBLE COMPOUNDS

    Rainer Muller

    Rainer Muller, Director, Research & Development, Pharmasol GmbH

  • Issues associated with poorly water-soluble molecules
  • Particle size reduction to improve performance
  • Utilizing NanoCrystal technology
  • Controlled release by a combination of NanoCrystal-pellets
  • Controlled release from coated NanoCrystals
  • Future opportunities for targeted NanoCrystal reagents
  • 12:20 Networking Lunch

    13:50 OVERCOMING THE BLOOD-BRAIN BARRIER

    Matthew Roe

    Matthew Roe, Senior Director, Business Development & Licensing, Genzyme

  • The challenge of CNS drug delivery
  • Current alternate approaches to CNS delivery
  • An explanation of Genzyme’s LipoBridge™ technology
  • Potential applications for CNS drug delivery
  • Recent results and future developments
  • 14:30 SUPERCRITICAL FLUID TECHNOLOGY

    Joel Richard

    Joel Richard, Director, Pharmaceutical Development, Serono

  • Parenteral delivery of therapeutic proteins: sustained-release microparticulate formulations
  • Oral delivery of poorly soluble drugs: enhancement of dissolution rate, control of particle size and morphology
  • Pulmonary delivery: design of powders with appropriate features
  • 15:10 Afternoon Tea

    15:40 ADVANCED DRUG DELIVERY DEVELOPMENTS IN THE TREATMENT OF DIABETES

    Tomas Landh

    Tomas Landh, Research Scientist, Novo Nordisk

  • Diabetes and ADDT – optimal marriage?
  • Overview of ADDT for treatment of diabetes
  • Overview of analogs/derivatives for treatment of diabetes
  • 16:20 NUCLEIC ACID AGENTS

    Martin Woodle

    Martin Woodle, President & CSO, Intradigm Corporation

  • Analysis of siRNA pharmacology and challenges for use as a therapeutic agent
  • Analysis of "multi-targeted" therapeutic strategies for blocking tumour angiogenesis
  • Development of siRNA combinations to rapidly develop "multi-targeted" therapeutics
  • Development of tissue-targeted nanoparticle systems for siRNA therapeutic development
  • Use of siRNA nanoparticle systems for multi-targeted anti-angiogenic therapeutics for cancer
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    +

    Workshops

    Enhancing & Protecting IP in Drug Delivery
    Workshop

    Enhancing & Protecting IP in Drug Delivery

    The Grange Holborn Hotel
    15th February 2006
    London, United Kingdom

    The Grange Holborn Hotel

    50-60 Southampton Row
    London WC1B 4AR
    United Kingdom

    The Grange Holborn Hotel

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.